68Ga标记成纤维细胞活化蛋白抑制剂PET/CT评估Erdheim-Chester病的效能:与18F-FDG PET/CT的比较
这项前瞻性队列研究纳入14例经组织学确诊的Erdheim-Chester病(ECD)患者,在1周内分别行68Ga-FAPI PET/CT与18F-FDG PET/CT。68Ga-FAPI PET/CT检出67个病灶中的64个,18F-FDG PET/CT检出51个(P=0.004);心脏、肺或胸膜、腹膜或网膜、肾或肾周浸润的SUVmax均以68Ga-FAPI更高。作者认为68Ga-FAPI PET/CT检出能力优于18F-FDG PET/CT,是有前景的评估工具。
要点
- 14例组织学确诊ECD患者中,骨受累占100%,心脏与肺各占57.1%。
- 68Ga-FAPI PET/CT检出67个病灶中的64个,18F-FDG PET/CT检出51个(P=0.004)。
- 心脏、肺或胸膜、腹膜或网膜、肾或肾周浸润的SUVmax均以68Ga-FAPI更高。
核心结论
- 68Ga-FAPI PET/CT的检出能力优于18F-FDG PET/CT,并在心脏、肺、腹膜和肾脏等多器官病灶中具有更好的图像对比度和更高的SUVmax。
- 68Ga-FAPI PET/CT是评估ECD患者病理特征和疾病范围的有前景工具。
研究设计与样本
- 前瞻性队列研究,纳入14例经组织学确诊的Erdheim-Chester病(ECD)患者。
- 每例患者在1周内均接受68Ga-FAPI PET/CT与18F-FDG PET/CT检查。
- 比较两种检查在受累器官病灶的阳性率和SUVmax。
主要发现
- 最常受累器官为骨(100%)、心脏(57.1%)、肺(57.1%)、肾(42.9%)、腹膜或网膜(35.7%),其他常见表现为颅内浸润(50%)和皮肤浸润(35.7%)。
- 68Ga-FAPI PET/CT检出14例患者67个病灶中的64个,18F-FDG PET/CT检出67个中的51个(P=0.004)。
- 心脏SUVmax为68Ga-FAPI 4.9±2.4 vs 18F-FDG 2.8±1.2(P=0.050)。
- 肺或胸膜SUVmax为68Ga-FAPI 6.8±4.9 vs 18F-FDG 3.1±1.3(P=0.025);腹膜或网膜为5.7±3.6 vs 2.8±1.7(P=0.032);肾或肾周浸润为4.9±1.2 vs 2.9±1.1(P=0.009)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Erdheim-Chester disease (ECD) involves multiple organs and tissues and has diverse manifestations, which makes it difficult to distinguish lesions caused by ECD from those caused by other diseases. Variable degrees of fibrosis are present in ECD. Therefore, we conducted a prospective cohort study to explore the ability of 68Ga fibroblast activation protein inhibitor (68Ga-FAPI) PET/CT to detect lesions in ECD patients. Methods: Fourteen patients diagnosed with ECD, as confirmed by histology, were included in this study. For every patient, 68Ga-FAPI PET/CT and 18F-FDG PET/CT were conducted within 1 wk. The positive rate and SUVmax of the lesions in the involved organs were compared between the examinations. Results: The most commonly involved organs were bone (100%), heart (57.1%), lung (57.1%), kidney (42.9%), and peritoneum or omentum (35.7%); other common manifestations were intracranial infiltration (50%) and cutaneous infiltration (35.7%). 68Ga-FAPI PET/CT detected 64 of 67 lesions in 14 patients, whereas 18F-FDG PET/CT detected 51 of 67 lesions (P = 0.004). The SUVmax for 68Ga-FAPI PET/CT was significantly higher than the SUVmax for 18F-FDG PET/CT of the heart (4.9 ± 2.4 vs. 2.8 ± 1.2, respectively; P = 0.050), lung or pleura (6.8 ± 4.9 vs. 3.1 ± 1.3, respectively; P = 0.025), peritoneum or omentum (5.7 ± 3.6 vs. 2.8 ± 1.7, respectively; P = 0.032), and kidney or perinephric infiltration (4.9 ± 1.2 vs. 2.9 ± 1.1, respectively; P = 0.009). Conclusion: The detectivity of 68Ga-FAPI PET/CT is superior to that of 18F-FDG PET/CT. Moreover, 68Ga-FAPI PET/CT has a better image contrast and higher SUVmax for lesions in multiple organs including the heart, lungs, peritoneum, and kidneys. 68Ga-FAPI PET/CT is a promising tool to assess pathologic features and disease extent in ECD patients.
引用
- Ma J, Yang Q, Huo L, et al. Performance of 68Ga-Labeled Fibroblast Activation Protein Inhibitor PET/CT in Evaluation of Erdheim-Chester Disease: A Comparison with 18F-FDG PET/CT. J Nucl Med. 2023. PMID: 37474266. doi:10.2967/jnumed.123.265691
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。